ACRS News and Press, Aclaris Therapeutics Inc. From 08/01/19

WAYNE, Pa., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory and dermatological diseases, today announced it will report financial results for the second quarter 2019, Thursday, August 8 th ...

NEW YORK , July 31, 2019 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Aclaris Therapeutics, Inc. ("Aclaris" or the "Company") (NASDAQ: ACRS) of the September 30, 2019 deadline to seek the role of lead plaintiff in a federal ...

2U (NASDAQ: TWOU ) -41%  on Q2 earnings . More news on: 2U, Inc., Sigma Labs, Inc., T2 Biosystems, Inc., Stocks on the move, Read more ...

Aclaris Therapeutics (NASDAQ: ACRS ) says that its Phase 2 trial of ATI-501 oral in patients with Alopecia Areata met its primary endpoint . More news on: Aclaris Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more ...

ATI-501 achieved statistically significant improvement over placebo in several measures of hair growth, including the primary endpoint and certain secondary endpoints of the trial. ATI-501 was generally well-tolerated at all doses.  No serious adverse events or thromboembolic ...

Rigel Pharmaceuticals' ( RIGL ) Tavalisse, launched in mid-2018, is experiencing sales growth but competitors exist that could potentially reduce peak sales. RIGL's partnered pipeline provides a source of potentially good news to offset any bad news regarding advances from RIGL's competitors...

Gainers:  Camber Energy (NYSEMKT: CEI ) +107% . Acacia Communications (NASDAQ: ACIA ) +35% . Electrameccanica Vehicles (NASDAQ: SOLO ) +26% . Xenetic Biosciences (NASDAQ: XBIO ) +16% . iFresh Inc. (NASDAQ: IFMK ) +15% . Atreca (NASDAQ: BCEL ) +15% . Pareteum Corporation (NASDAQ:...

The USPTO has issued Aclaris Therapeutics (NASDAQ: ACRS ), Patent No. 10,335,391 covering methods of treating facial erythema associated with rosacea using a 1.0% w/w oxymetazoline hydrochloride composition. More news on: Aclaris Therapeutics, Inc., Healthcare stocks news, Read more ...

Issuance of U.S. Patent No. 10,335,391 Further Strengthens Aclaris’ RHOFADE Patent Portfolio WAYNE, Pa., July 09, 2019 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory and dermatological dis...

WAYNE, Pa., July 03, 2019 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory and dermatological diseases, today announced the appointment of Maxine Gowen to its board of directors, effective July 2, 2019. ...